Results 1 to 10 of about 206,426 (300)

Antiphospholipid Antibodies to Domain I of Beta-2-Glycoprotein I Show Different Subclass Predominance in Comparison to Antibodies to Whole Beta-2-glycoprotein I [PDF]

Frontiers in Immunology, 2018
Antiphospholipid antibodies (aPL), the serological hallmark of antiphospholipid syndrome (APS), are a heterogeneous group of autoantibodies raised against circulating blood proteins.
Thomas McDonnell, Bahar Artim-Esen, Chris Wincup, Vera M. Ripoll, David Isenberg, Ian P. Giles, Anisur Rahman, Charis Pericleous   +7 more
doaj   +10 more sources

The Significance of Anti-Beta-2-Glycoprotein I Antibodies in Antiphospholipid Syndrome [PDF]

Antibodies, 2016
Antiphospholipid syndrome (APS) is a thrombophilic disorder that classically presents with vascular thrombosis and/or obstetric complications. APS is associated with antiphospholipid antibodies: a heterogeneous group of autoantibodies that are directed ...
Anna Brusch
doaj   +8 more sources

PEGylated Domain I of Beta-2-Glycoprotein I Inhibits Thrombosis in a Chronic Mouse Model of the Antiphospholipid Syndrome [PDF]

Frontiers in Immunology, 2022
Antiphospholipid syndrome (APS) is an autoimmune disorder in which autoantibodies cause clinical effects of vascular thrombosis and pregnancy morbidity. The only evidence-based treatments are anticoagulant medications such as warfarin and heparin.
Rohan Willis, Thomas C. R. McDonnell, Charis Pericleous, Emilio B. Gonzalez, Alvaro Schleh, Zurina Romay-Penabad, Ian P. Giles, Anisur Rahman   +7 more
doaj   +5 more sources

B cell-derived anti-beta 2 glycoprotein I antibody mediates hyperhomocysteinemia-aggravated hypertensive glomerular lesions by triggering ferroptosis [PDF]

Signal Transduction and Targeted Therapy, 2023
Hyperhomocysteinemia (HHcy) is a risk factor for chronic kidney diseases (CKDs) that affects about 85% CKD patients. HHcy stimulates B cells to secrete pathological antibodies, although it is unknown whether this pathway mediates kidney injury.
Xing Du, Xiaolong Ma, Ying Tan, Fangyu Shao, Chun Li, Yang Zhao, Yutong Miao, Lulu Han, Guohui Dang, Yuwei Song, Dongmin Yang, Zhenling Deng, Yue Wang, Changtao Jiang, Wei Kong, Juan Feng, Xian Wang   +16 more
doaj   +5 more sources

Specific domain V reduction of beta-2-glycoprotein I induces protein flexibility and alters pathogenic antibody binding [PDF]

Scientific Reports, 2021
Beta-2-glycoprotein I (β2GPI) is a blood protein and the major antigen in the autoimmune disorder antiphospholipid syndrome (APS). β2GPI exists mainly in closed or open conformations and comprises of 11 disulfides distributed across five domains.
Ina Buchholz, Thomas McDonnell, Peter Nestler, Sudarat Tharad, Martin Kulke, Anna Radziszewska, Vera M. Ripoll, Frank Schmidt, Elke Hammer, Jose L. Toca-Herrera, Anisur Rahman, Mihaela Delcea   +11 more
doaj   +5 more sources

Beyond antibodies: Beta-2 glycoprotein I as the unsung guardian of pregnancy. [PDF]

PLoS ONE
The physiological function of beta 2 glycoprotein I (β2GPI) itself is not well understood, other than that it is a primary antigen to anti-phospholipid antibodies in the autoimmune disease antiphospholipid syndrome.
Kazunobu Yagi, Reina Komatsu, Hitomi Nakamura, Kazuya Mimura, Masayuki Endo, Takuji Tomimatsu, Tadashi Kimura   +6 more
doaj   +5 more sources

Immune Complexes of Beta-2-Glycoprotein I and IgA Antiphospholipid Antibodies Identify Patients With Elevated Risk of Thrombosis and Early Mortality After Heart Transplantation [PDF]

Frontiers in Immunology, 2019
Background: The presence of anti-Beta 2 glycoprotein antibodies (aB2GP1) of IgA isotype is common in patients with functional impairment of the organs in which B2GP1 is elaborated.
Manuel Serrano, Manuel Serrano, Laura Morán, Jose Angel Martinez-Flores, Esther Mancebo, Daniel Pleguezuelo, Oscar Cabrera-Marante, Juan Delgado, Antonio Serrano, Antonio Serrano   +9 more
doaj   +4 more sources

Beta 2 glycoprotein I and neutrophil extracellular traps: Potential bridge between innate and adaptive immunity in anti-phospholipid syndrome [PDF]

Frontiers in Immunology, 2023
Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by recurrent vascular thrombosis and miscarriages in the absence of known causes.
Claudia Grossi, Nagaja Capitani, Nagaja Capitani, Marisa Benagiano, Cosima Tatiana Baldari, Chiara Della Bella, Paolo Macor, Francesco Tedesco, Maria Orietta Borghi, Maria Orietta Borghi, Norma Maugeri, Mario Milco D’Elios, Pier Luigi Meroni   +12 more
doaj   +3 more sources

Beta‐2‐Glycoprotein‐I Deficiency Could Precipitate an Antiphospholipid Syndrome‐like Prothrombotic Situation in Patients With Coronavirus Disease 2019 [PDF]

ACR Open Rheumatology, 2021
Objective Patients with coronavirus disease 2019 (COVID‐19) present coagulation abnormalities and thromboembolic events that resemble antiphospholipid syndrome (APS).
Manuel Serrano, Gerard Espinosa, Antonio Lalueza, Luz Yadira Bravo‐Gallego, Raquel Diaz‐Simón, Sara Garcinuño, Javier Gil‐Etayo, Jorge Moises, Laura Naranjo, Sergio Prieto‐González, Estibaliz Ruiz‐Ortiz, Beatriz Sánchez, Ana Belen Moreno‐Castaño, Carmen Díaz‐Pedroche, Odette Viñas‐Gomis, Ricard Cervera, Antonio Serrano, the APS‐COVID 19 Study Group/European Forum on Antiphospholipid Antibodies   +17 more
doaj   +3 more sources

Cardiolipin interacts with beta-2-glycoprotein I and forms an open conformation-Mechanisms analyzed using hydrogen/deuterium exchange. [PDF]

Protein Sci, 2021
Beta‐2‐glycoprotein I (β2GPI) is the major antigen for the antiphospholipid antibodies in the antiphospholipid syndrome. The exposed epitope in domain I of β2GPI can be recognized by the anti‐β2GPI antibody.
Tang KT, Wu TY, Chen HH, Lin CC, Hsu YH.
europepmc   +4 more sources